+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer: evidence from 261 cases in Israel, 1976-1999



Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer: evidence from 261 cases in Israel, 1976-1999



European Journal of Medical Genetics 51(2): 141-147



To evaluate the potential contribution of mutations in the BRCA1 and BRCA2 genes to male breast cancer (MBC), we expanded a previous study to screen a total of 261 Israeli men diagnosed with breast carcinoma. A total of 21 BRCA2 6174delT and 8 BRCA1 185delAG mutations were found. Similar frequencies of BRCA1 and BRCA2 mutation carriers were found among Ashkenazi (12.8%) and non-Ashkenazi Jews (9.1%). The combined prevalence of BRCA1/BRCA2 founder mutations among Ashkenazi Jewish men is slightly higher than for women, due to a higher frequency of BRCA2 mutations.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 033391321

Download citation: RISBibTeXText

PMID: 18158280

DOI: 10.1016/j.ejmg.2007.11.001


Related references

The Jewish Ashkenazi founder mutations in the BRCA1/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer. American Journal of Human Genetics 65(3): 921-924, 1999

Prevalence of BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish (AJ) families with breast cancer (BC) and pancreatic cancer (PC). Journal of Clinical Oncology 23(16_suppl): 9549-9549, 2016

Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. American Journal of Human Genetics 60(5): 1059-1067, 1997

Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families. Neoplasma 53(2): 97-102, 2006

An evaluation of BRCA1 and BRCA2 founder mutations penetrance estimates for breast cancer among Ashkenazi Jewish women. Genetics in Medicine 7(1): 34-39, 2005

Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women. JAMA Oncology 3(12): 1647-1653, 2017

Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families. Journal of Medical Genetics 39(8): 611-614, 2002

Screening for breast cancer by molecular testing for three founder mutations in the BRCA1 and BRCA2 genes among women of Ashkenazi Jewish heritage. Journal of Medical Screening 22(3): 109-111, 2015

Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer. Journal of Medical Genetics 36(5): 369-373, 1999

Estimate of the average age-specific cumulative risk of breast cancer for the Ashkenazi founder mutations in BRCA1 and BRCA2 from the Breast Cancer Family Registry. Cancer Epidemiology Biomarkers & Prevention 11(10 Part 2): 1164s, October, 2002

The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. American Journal of Human Genetics 60(3): 505-514, 1997

Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. Cancer 118(2): 493-499, 2012

Significantly lower rates of BRCA1/BRCA2 founder mutations in Ashkenazi women with sporadic compared with familial early onset breast cancer. European Journal of Cancer 36(8): 983-986, 2000

Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. Journal of the National Cancer Institute (Bethesda) 91(14): 1241-1247, July 21, 1999

Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer. Human Mutation 16(6): 491-501, 2000